Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.
Abstract
Highly potent, but poorly water-soluble, drug candidates are common outcomes of contemporary drug discovery programmes and present a number of challenges to drug development - most notably, the issue of reduced systemic exposure after oral administration. However, it is increasingly apparent that formulations containing natural and/or synthetic lipids present a viable means for enhancing the oral bioavailability of some poorly water-soluble, highly lipophilic drugs. This Review details the mechanisms by which lipids and lipidic excipients affect the oral absorption of lipophilic drugs and provides a perspective on the possible future applications of lipid-based delivery systems. Particular emphasis has been placed on the capacity of lipids to enhance drug solubilization in the intestinal milieu, recruit intestinal lymphatic drug transport (and thereby reduce first-pass drug metabolism) and alter enterocyte-based drug transport and disposition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conventional absorption and bioavailability assessments, and the body-weight regressions built upon them, implicitly assume the portal route and seldom quantify the lymphatic contribution, even though, for suitable compounds, it can represent a substantial fraction of systemic exposure [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“This route becomes quantitatively relevant only for compounds that combine high lipophilicity with appreciable long-chain triglyceride solubility, for which a log P greater than 5 and a lipid solubility above approximately 50 mg/g are commonly cited as approximate thresholds [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“Because lymphatic delivery reaches the systemic circulation while bypassing hepatic first-pass metabolism, it can materially increase the oral bioavailability of affected compounds and lower their apparent first-pass loss in a manner that a body-weight regression of systemic clearance or volume cannot anticipate [28,29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“For highly lipophilic drugs, a fraction of the absorbed dose can bypass the portal circulation entirely and reach the systemic circulation via the intestinal lymphatics, associated with triglyceride-rich lipoproteins (chylomicrons) assembled within the enterocyte [28,29].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“The extent of transport is highly sensitive to prandial state and to the type and quantity of co-administered lipid, which differ across preclinical study designs and between the fasted conditions typical of first-in-human protocols and the fed conditions under which lymphatic transport is greatest [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734 · cited 1×
“This is especially the case when potent, but highly lipophilic, drug candidates arise from complex chemical scaffolds and multiple high-throughput activity screen”
BackgroundNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., Kwiterovich, P., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,648
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 1×
“In addition to the potential effect of lipidic excipients (primarily surfactants) on P-gp-mediated efflux, Benet and co-workers have recently suggested that high-fat meals could inhibit P-g”
BackgroundSelf-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
Neslihan Gursoy, R., & Benita, S. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.02.001 · Cited by 1,358
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J.-M. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,301
Cited by
Items 601–700 of 1,003
Onodera, T., Kuriyama, I., Andoh, T., Ichikawa, H., SAKAMOTO, Y., Lee, E., & Mizushina, Y. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2186 · Cited by 51
“Emulsion-based delivery systems are being increasingly used in the pharmaceutical industry to incorporate lipophilic bioactive components (25).”
BackgroundBala, V., Rao, S., Bateman, E. H., Keefe, D. M. K., Wang, S., & Prestidge, C. A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00591 · Cited by 51
El‐Say, K. M., Ahmed, T. A., Ahmed, O. A. A., Hosny, K. M., & Abd-Allah, F. I. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.01.001 · Cited by 51
Brocks, D. R., & Davies, N. M. (2018) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30217 · Cited by 52
Lin, P., Chen, K., Miao, Y., Chen, H., Lin, K., Chen, C., Yeh, C., Chang, Y., & Sung, H. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201809015 · Cited by 51
Therapeutic Nanoemulsion: Concept to Delivery
Barkat, M. A., Harshita, Rizwanullah, M., Pottoo, F. H., Beg, S., Akhter, S., & Ahmad, F. J. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200317140600 · Cited by 51
Zhang, R., Dong, K., Wang, Z., Miao, R., Lu, W., & Wu, X. Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081261 · Cited by 51
“Particularly, for LNS containing triglycerides, cholesterol esters or long chain fatty acids, they are incorporated into the large lipoprotein chylomicrons (75–1200 nm) upon re-esterification and preferentially trafficked via the intestinal lymphatic system, thus effectively evading first-pass metabolism in the liver…”
BackgroundCheng, L., Ye, A., Hémar, Y., & Singh, H. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.10.075 · Cited by 51
Khan, S., Baboota, S., Ali, J., Narang, R. S., & Narang, J. K. (2015) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2015.1040414 · Cited by 51
Jin, S.-X., Fu, S., Han, J., Jin, S.-Y., Lv, Q., Lü, Y., Qi, J., Wu, W., & Yuan, H. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.702770 · Cited by 51
“Thirdly, the presence of phospholipid in GL-SDC/ PL-MMs reduced gastric emptying and the colloidal structures of the GL-SDC/PL-MMs provided a series of enduring lipophilic phases within which drugs might reside during gastrointestinal transit, thereby preventing precipitation and enhancing absorption of the drugs (Por…”
BackgroundChen, L., Lv, Y., & Zhong, F. (2023) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2023.109397 · Cited by 50
Zhang, X., Yi, Y., Qi, J., Lü, Y., Tian, Z., Xie, Y., Yuan, H., & Wu, W. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.05.014 · Cited by 50
Camelo, S. R. P., Franceschi, S., Pérez, E., Fullana, S. G., & Ré, M. I. (2015) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2015.1103746 · Cited by 50
“The organogel melting enthalpy (DHm) combines at least two distinct energetic contributions: (1) the melting enthalpy of the fibers (which should be more or less constant and independent of the solvent used if the fibers comprise pure gelator molecules organized in a similar and regular structure) and (2) the enthalpy”
BackgroundPham, K., Li, D., Guo, S., Penzak, S. R., & Dong, X. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.001 · Cited by 50
“Lipid NPs can be taken up by Peyer’s patch or as chylomicron-like particles in the intestine by which they enter the lymphatic circulation [43,44].”
BackgroundFrueh, L., Li, Y., Mather, M. W., Li, Q., Pou, S., Nilsen, A., Winter, R. W., Forquer, I., Pershing, A. M., Xie, L. H., et al. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00062 · Cited by 50
Tay, E., Nguyen, T., Ford, L., Williams, H. D., Benameur, H., Scammells, P. J., & Porter, C. J. H. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics12010017 · Cited by 50
“Samples are taken over time and c ntrifuged to s parat the digest into an oil phase, an aqueous phase, and pellet phase, which are t en nalyzed for drug content [28].”
BackgroundMethodInfluentialSelf-citationQian, K., Stella, L., Jones, D. S., Andrews, G. P., Du, H., & Tian, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060889 · Cited by 50
“To combat these challenges, various formulation strategies such as amorphous solids [9,10], nanocrystals [11,12], liposomes [13,14], micro/nano-emulsifying systems [15] and co-crystals [16] have been developed.”
BackgroundZhang, Z., Huang, Y. L., Gao, F., Bu, H., Gu, W., & Li, Y. (2011) · Nanoscale · doi:10.1039/c0nr00879f · Cited by 50
Memvanga, P. B., & Véronique Préat, A. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.05.004 · Cited by 50
“Indeed, it influences the speed and the quantity of released and absorbed compounds [18,37], but the impact of these effects remains controversial [22,38].”
BackgroundMediation of in Vitro Cytochrome P450 Activity by Common Pharmaceutical Excipients
Martin, P., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400175n · Cited by 50
Sell, D. K., Berthelsen, R., Sassene, P. J., Selen, A., & Müllertz, A. (2016) · AAPS PharmSciTech · doi:10.1208/s12249-016-0649-1 · Cited by 50
Guo, Z., Liu, Y., & Luo, Y. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2119204 · Cited by 49
“Unsaturated fatty acids in general have greater effect in promoting liposoluble substance absorption into the lymphatic system than saturated fatty acids (Porter, Trevaskis, and Charman 2007).”
BackgroundShah, M. K., Madan, P. L., & Lin, S. (2014) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2014.938857 · Cited by 49
Lee, K. W. Y., Porter, C. J. H., & Boyd, B. J. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23384 · Cited by 49
Self-citationSun, C., Wang, J., Liu, J., Qiu, L., Zhang, W., & Zhang, L. (2013) · AAPS PharmSciTech · doi:10.1208/s12249-013-9924-6 · Cited by 49
Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative
Alrushaid, S., Sayre, C. L., Yáñez, J. A., Forrest, M. L., Senadheera, S. N., Burczynski, F. J., Löbenberg, R., & Davies, N. M. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9030035 · Cited by 49
Jain, A., Kaur, R., Beg, S., Kushwah, V., Jain, S., & Singh, B. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0514-8 · Cited by 49
Molecular bionics – engineering biomaterials at the molecular level using biological principles
Rodríguez‐Arco, L., Poma, A., Ruiz‐Pérez, L., Scarpa, E., Ngamkham, K., & Battaglia, G. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.044 · Cited by 50
“Indeed, different sources exhibit different contents and species of phospholipids [86,100,101].”
BackgroundFeng, W., Qin, C., Chu, Y., Berton, M., Lee, J. B., Zgair, A., Bettonte, S., Stocks, M. J., Constantinescu, C. S., Barrett, D. A., et al. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.02.013 · Cited by 50
Momoh, M. A., Kenechukwu, F. C., & Attama, A. A. (2013) · Drug Delivery · doi:10.3109/10717544.2013.779329 · Cited by 49
“Studies have shown that lipid-based excipients can influence oral absorption via various physiological effects, such as retarded gastric emptying (Porter & Trevaskis, 2007), stimulating bile flow and secretion of pancreatic juice, increasing the membrane lipid fluidity or acting directly onto…”
BackgroundLee, J., Cho, Kim, Lee, & Baek, M.-K. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s37338 · Cited by 49
The feasibility of oral targeted drug delivery: Gut immune to particulates?
Ren, Y., Wu, W., & Zhang, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.020 · Cited by 48
The future of microfluidic assays in drug development
Wen, Y., & Yang, S. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.10.1237 · Cited by 48
“Emulsions and double emulsions are increasingly being developed for making drugs with longer life time in circulation and increased bioavailability [147] .”
BackgroundAhmad, N., Ahmad, R., Al-Qudaihi, A., Alaseel, S. E., Fita, I. Z., Khalid, M. S., Pottoo, F. H., & Bolla, S. R. (2019) · 3 Biotech · doi:10.1007/s13205-019-1885-3 · Cited by 48
RetractedKarthivashan, G., Ganesan, P., Park, S., Lee, H., & Choi, D. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119704 · Cited by 48
McClements, D. J. (2020) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-032519-051834 · Cited by 48
Tablets and minitablets prepared from spray-dried SMEDDS containing naproxen
Čerpnjak, K., Pobirk, A. Z., Vrečer, F., & Gašperlin, M. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.099 · Cited by 48
Devraj, R., Williams, H. D., Warren, D. B., Kazi, M., Porter, C. J. H., & Pouton, C. W. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.04.036 · Cited by 48
Self-citationSelf-Emulsifying Drug Delivery Systems (SEDDS) in Pharmaceutical Development
Santana, M. H. A. (2015) · Journal of Advanced Chemical Engineering · doi:10.4172/2090-4568.1000130 · Cited by 48
Jiao, W., Li, L., Yu, A., Zhao, D., Sheng, B., Aikelamu, M., Li, B., & Zhang, X. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b04287 · Cited by 48
Cracking the intestinal lymphatic system window utilizing oral delivery vehicles for precise therapy
Miao, Y., Xu, T., Gong, Y., Chen, A., Zou, L., Jiang, T., & Shi, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01991-3 · Cited by 47
Swarnakar, N. K., Thanki, K., & Jain, S. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.03.003 · Cited by 47
Modgill, V., Garg, T., Goyal, A. K., & Rath, G. (2014) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2014.924007 · Cited by 47
“The conventional approaches such as use of surfactant (Bakatselou et al. 1991), lipid-based systems (O’Driscoll 2002, Charman 2000, Porter et al. 2007), solubilizer (Ahuja et al. 2007), prodrugs (Hussain and Rytting 1974), and permeation enhancers (Babu et al. 2010) has been exploited as a probable…”
MethodJoyce, P. M., Whitby, C. P., & Prestidge, C. A. (2016) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2016.10.003 · Cited by 47
Khurana, R. K., Beg, S., Burrow, A. J., Vashishta, R. K., Katare, O. P., Kaur, S., Kesharwani, P., Singh, K. K., & Singh, B. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.09.001 · Cited by 47
Lymphatic system identification, pathophysiology and therapy in the cardiovascular diseases
Hu, D. M., Li, L., Li, S., Wu, M., Ge, N., Cui, Y., Lian, Z., Song, J., & Chen, H. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.06.002 · Cited by 47
Progress on cocrystallization of poorly soluble NME's in the last decade
Roy, P. S., & Ghosh, A. (2020) · CrystEngComm · doi:10.1039/d0ce01276a · Cited by 47
Nora, G.-I., Venkatasubramanian, R., Strindberg, S., Siqueira, S. D. V. S., Pagano, L., Romanski, F. S., Swarnakar, N. K., Rades, T., & Müllertz, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.057 · Cited by 48
“Thereby SNEDDS are bypassing the potentially absorption limiting dissolution step for poorly soluble drugs in the GIT, and improve drug absorption [8,9].”
BackgroundQi, J., & Ping, Q. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s18821 · Cited by 47
Li, Y., Xiao, H., & McClements, D. J. (2012) · Food Biophysics · doi:10.1007/s11483-012-9272-1 · Cited by 47
Li, S., Pollock‐Dove, C., Dong, L. C., Chen, J., Creasey, A. A., & Dai, W. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200352q · Cited by 47
Rajput, A., Pingale, P., Telange, D. R., Chalikwar, S. S., & Borse, V. B. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102934 · Cited by 46
Bioavailability Enhancement and Formulation Technologies of Oral Mucosal Dosage Forms: A Review
Bácskay, I., Arany, P., Fehér, P. S., Józsa, L., Vasvári, G., Nemes, D., Pető, Á., Kósa, D., Haimhoffer, Á., Ujhelyi, Z., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020148 · Cited by 46
Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment
Nelson, A. G., Zhang, X., Ganapathi, U., Székely, Z., Flexner, C. W., Owen, A., & Sinko, P. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.042 · Cited by 48
Xia, D., Cui, F., Gan, Y., Mu, H., & Yang, M. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23830 · Cited by 46
Piazzini, V., Rosseti, C., Bigagli, E., Luceri, C., Bilia, A. R., & Bergonzi, M. C. (2017) · Planta Medica · doi:10.1055/s-0043-110052 · Cited by 46
“Lipid carriers promote absorption by presenting the drug to the gastrointestinal tract in a solubilized form, increasing the solubilization capacity of the gastrointestinal fluids and in many cases, generating transiently supersaturated drug concentrations [19, 20].”
Zhang, Y., Zhu, W., Zhang, H., Han, J., Zhang, L., Lin, Q., & Ai, F. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.09.023 · Cited by 46
Ghassemi, S., Haeri, A., Shahhosseini, S., & Dadashzadeh, S. (2018) · AAPS PharmSciTech · doi:10.1208/s12249-018-1118-9 · Cited by 46
Pandit, S., Roy, S., Pillai, J. D., & Banerjee, S. (2020) · ACS Omega · doi:10.1021/acsomega.9b03523 · Cited by 46
Oral self-emulsifying drug delivery systems, from biopharmaceutical to technical formulation aspects
Kuentz, M. (2011) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(11)50002-4 · Cited by 46
Valetti, S., Xia, X., Costa-Gouveia, J., Brodin, P. M., Bernet‐Camard, M., Andersson, M. E., & Feiler, A. A. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0364 · Cited by 46
Otsuka, K., Yamamoto, Y., Matsuoka, R., & Ochiya, T. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700080 · Cited by 46
“[85-87] It has been highly anticipated that realizing the development of functional foods would contribute to health promotion worldwide by connecting underexploited but competent natural products to miRNAs as a tool for health management.”
BackgroundEffect of surfactant molecular structure on Progesterone solubilization
Vinarov, Z., Dobreva, P., & Tcholakova, S. S. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.09.014 · Cited by 46
Phan, S., Hawley, A. M., Mulet, X., Waddington, L. J., Prestidge, C. A., & Boyd, B. J. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1108-2 · Cited by 45
Yeap, Y. Y., Trevaskis, N. L., & Porter, C. J. H. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400035z · Cited by 45
Self-citationEpigenetic and antitumor effects of platinum(IV)-octanoato conjugates
Novohradský, V., Zanellato, I., Marzano, C., Prachařová, J., Kašpárková, J., Gibson, D., Gandin, V., Osella, D., & Brabec, V. (2017) · Scientific Reports · doi:10.1038/s41598-017-03864-w · Cited by 45
The artificial membrane insert system as predictive tool for formulation performance evaluation
Berben, P., Brouwers, J., & Augustijns, P. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.12.025 · Cited by 45
Molina, C. V., Juliana Gobbi de, L. I. M. A., Moraes, I. C. F., & Pinho, S. C. (2018) · Food Science and Biotechnology · doi:10.1007/s10068-018-0425-y · Cited by 45
Huang, X., Li, T., & Li, S. (2022) · Current Research in Food Science · doi:10.1016/j.crfs.2022.100419 · Cited by 45
Mistry, P., Neagu, D. C., Trundle, P. R., & Vessey, J. D. (2015) · Soft Computing · doi:10.1007/s00500-015-1925-9 · Cited by 46
“For instance, studies have shown that vehicles can be selected to improve the solubility and/or permeability of a drug or to target the drug to a specific disease site (Loftsson 1998; Porter et al. 2007; Shin et al. 2009; Hans and Lowman 2002; Liu et al. 2011; Lee et al. 2003).”
BackgroundColloidal carriers for extended absorption window of furosemide
Sultan, A. A., El‐Gizawy, S. A., Osman, M. A., & Maghraby, G. M. E. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12516 · Cited by 45
“[12,13] The later mechanism is generally documented for most lipid-based systems including SMEDDS.”
BackgroundInfluentialA Mouse Model to Evaluate the Impact of Species, Sex, and Lipid Load on Lymphatic Drug Transport
Trevaskis, N. L., Caliph, S. M., Nguyen, G., Tso, P., Charman, W. N., & Porter, C. J. H. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1000-0 · Cited by 44
Self-citationIn Situ Monitoring of Nanostructure Formation during the Digestion of Mayonnaise
Salentinig, S., Amenitsch, H. W., & Yaghmur, A. (2017) · ACS Omega · doi:10.1021/acsomega.7b00153 · Cited by 44
Exploiting or overcoming the dome trap for enhanced oral immunization and drug delivery
Qi, J., Zhuang, J., Lv, Y., Lü, Y., & Wu, W. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.021 · Cited by 44
Alam, M. M., Najmi, A. K., Ahmad, I., Ahmad, F. J., Akhtar, M. J., Imam, S. S., & Akhtar, M. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1451873 · Cited by 44
“It has reported that lipid protects drug from acidic degradation, increases intestinal permeability, promotes oral absorption through lymphatic transport by reducing first pass metabolism and higher amount of drug loading which enhances the availabile of drug to the systemic circulation [14,15].”
BackgroundSolubilisation behaviour of poorly water-soluble drugs during digestion of solid SMEDDS
Vithani, K., Hawley, A. M., Jannin, V., Pouton, C. W., & Boyd, B. J. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.07.006 · Cited by 44
Tian, C., Guo, J., Wang, G., Sun, B., Na, K., Zhang, X., Xu, Z., Cheng, M., He, Z., & Sun, J. (2019) · Advanced Science · doi:10.1002/advs.201901810 · Cited by 44
A drift on liposomes to proliposomes: recent advances and promising approaches
Dhiman, N., Sarvaiya, J., & Mohindroo, P. (2022) · Journal of Liposome Research · doi:10.1080/08982104.2021.2019762 · Cited by 44
“They further form mixed vehicle or mesophase micelles that increase the solubility of hydrophobic drug candidates (Hildebrand et al. 2003, Porter et al. 2007, Chen et al. 2009).”
BackgroundLee, D. W., Marasini, N., Poudel, B. K., Kim, J. H., Cho, H. J., Moon, B. K., Choi, H.-G., Yong, C. S., & Kim, J. O. (2013) · Journal of Microencapsulation · doi:10.3109/02652048.2013.805837 · Cited by 44
“Although the exact mechanisms responsible for this enhanced absorption are not fully known, it is believed that various factors such as improved drug solubilization, increased membrane permeability and lymphatic transport may contribute significantly (O’Driscoll, 2002; Porter et al., 2007).”
BackgroundTrevaskis, N. L., McEvoy, C. L., McIntosh, M. P., Edwards, G. A., Shanker, R. M., Charman, W. N., & Porter, C. J. H. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0083-0 · Cited by 44
“High lipophilicity and low water solubility may lead to reduced drug absorption and bioavailability after oral administration, and compounds of this type often fail to progress into formal development ( 11 ).”
BackgroundResultInfluentialSelf-citationZhang, Z., Gao, F., Jiang, S., Chen, L., Liu, Z., Yu, H., & Li, Y. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.05.021 · Cited by 44
Agarwal, A., Kharb, V., & Saharan, V. A. (2014) · International Current Pharmaceutical Journal · doi:10.3329/icpj.v3i7.19079 · Cited by 44
Shangguan, M., Qi, J., Lü, Y., & Wu, W. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.005 · Cited by 44
Tan, O. J., Loo, H. L., Thiagarajah, G., Palanisamy, U. D., & Sundralingam, U. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153651 · Cited by 43
A.J. Board, Crowther, J. M., Acevedo-Fani, A., Meisrimler, C., Jameson, G. B., & Dobson, R. C. J. (2022) · Biophysical Reviews · doi:10.1007/s12551-021-00923-5 · Cited by 43
“Hydrophobic medicines are not easily delivered by oral or intravenous methods due to poor solubility, instability, and low membrane permeability (Porter et al. 2007; Savjani et al. 2012; Cho et al. 2018).”
BackgroundNesamony, J., Shah, I. S., Kalra, A. V., & Jung, R. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.814065 · Cited by 43
Elmarzugi, N. A., Eid, A. M., Enshasy, H. A. E., & Aziz, R. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s66180 · Cited by 43
Surfactants, Lipids, and Surface Chemistry
Kulkarni, V. S., & Shaw, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801024-2.00002-9 · Cited by 43
Apoferritin Nanocage Delivers Combination of Microtubule and Nucleus Targeting Anticancer Drugs
Ghosh, S., Mohapatra, S., Thomas, A., Bhunia, D., Saha, A., Das, G., Jana, B., & Ghosh, S. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b11798 · Cited by 43
Bioaccessibility of curcuminoids in buttermilk in simulated gastrointestinal digestion models
Fu, S., Augustin, M. A., Shen, Z., Ng, K., Sanguansri, L., & Ajlouni, S. (2015) · Food Chemistry · doi:10.1016/j.foodchem.2015.01.126 · Cited by 43
“that bile salts and lipids, such as free fatty acids, monoglycerides, diglycerides and glycerolphospholipids, significantly improved the aqueous solubilisation of some poorly water-soluble drugs (Porter et al., 2007).”
BackgroundMethodInfluentialZhang, Z., Huang, Y. L., Gao, F., Gao, Z., Bu, H., Gu, W., & Li, Y. (2011) · Nanomedicine · doi:10.2217/nnm.11.39 · Cited by 43
Sharma, G., Beg, S., Thanki, K., Katare, O. P., Jain, S., Kohli, K., & Singh, B. (2015) · RSC Advances · doi:10.1039/c5ra11687b · Cited by 43
Singh, G., & Pai, R. S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.913566 · Cited by 42
“Studies have shown that the type of absorption pathway and subsequent transportation of drug are significantly influenced by the long-chain triglycerides (LCTs) [9,10].”
BackgroundHiggins, J. D., Cartwright, M. E., & Templeton, A. C. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.03.016 · Cited by 42
Han, S., Hu, L., Gracia, Quach, T., Simpson, J. S., Edwards, G. A., Trevaskis, N. L., & Porter, C. J. H. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00195 · Cited by 42
“This medium has similar lipase activity when compared to the dog and human GI environment, and has been commonly used as a substitute to study the digestion/performance of lipid formulations 18 .”
MethodSelf-citationKhan, J., Rades, T., & Boyd, B. J. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00594 · Cited by 42
Lu, X., Zhu, J., Pan, Y., & Huang, Q. (2019) · Food & Function · doi:10.1039/c8fo02495b · Cited by 42
Lu, X., Zhang, H., Zheng, T., Liu, Q., Zhu, J., & Huang, Q. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b05372 · Cited by 42
Comparison of β-carotene loaded marine and egg phospholipids nanoliposomes
Hamadou, A. H., Huang, W.-C., Xue, C., & Mao, X. (2020) · Journal of Food Engineering · doi:10.1016/j.jfoodeng.2020.110055 · Cited by 42
Yang, Y. R., & McClements, D. J. (2013) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2013.05.018 · Cited by 42
Metadata
- Authors
- Porter, C. J. H., Trevaskis, N. L., & Charman, W. N.
- Affiliations
- Monash University (AU)
- Corresponding author
- Porter, Christopher J. H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-03
- Volume
- 6
- Issue
- 3
- Pages
- 231-248
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2069235788
- Cited by
- 1,824
- References
- 253
- Citations by year
- 2026: 88 · 2025: 87 · 2024: 67 · 2023: 89 · 2022: 119 · 2021: 108 · 2020: 140 · 2019: 101 · 2018: 117 · 2017: 121 · 2016: 125 · 2015: 119 · 2014: 120 · 2013: 128 · 2012: 94
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- lipid-based drug delivery, oral bioavailability, lipophilic drugs, poorly water-soluble drugs, lipid excipients, first-pass metabolism, lipid-based formulations
- MeSH terms
- Administration, Oral, Animals, Pharmaceutical Preparations, Excipients, Humans, Intestinal Absorption, Lipids, Drug Design, Drug Delivery Systems, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.